5324062025-01-012025-03-315324062025-03-315324062024-03-315324062024-04-012025-03-315324062025-01-012025-03-31in-capmkt:OtherExpenses1Member5324062024-04-012025-03-31in-capmkt:OtherExpenses1Member5324062025-01-012025-03-31in-capmkt:ReportableSegments1Member5324062025-01-012025-03-31in-capmkt:ReportableSegments2Member5324062024-04-012025-03-31in-capmkt:ReportableSegments1Member5324062024-04-012025-03-31in-capmkt:ReportableSegments2Member5324062025-01-012025-03-31in-capmkt:ReportableSegments1Member5324062025-01-012025-03-31in-capmkt:ReportableSegments2Member5324062024-04-012025-03-31in-capmkt:ReportableSegments1Member5324062024-04-012025-03-31in-capmkt:ReportableSegments2Member5324062025-01-012025-03-31in-capmkt:ReportableSegments1Member5324062025-03-31in-capmkt:ReportableSegments1Member5324062025-01-012025-03-31in-capmkt:ReportableSegments2Member5324062025-03-31in-capmkt:ReportableSegments2Member5324062025-01-012025-03-31in-capmkt:ReportableSegments1Member5324062025-03-31in-capmkt:ReportableSegments1Member5324062025-01-012025-03-31in-capmkt:ReportableSegments2Member5324062025-03-31in-capmkt:ReportableSegments2Member5324062025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532406AVANTELNOTLISTEDINE005B01027AVANTEL LIMITEDMain BoardEquity2024-04-012025-03-312025-04-262025-04-18INRLakhsQuarterlyFourth quarterMulti segment2025-04-2611:00:002025-04-2614:45:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated4926130004822000497435000123133000088420001331510006594000293570001114510004125280008490700008490700026271000-220600024065000060842000000060842000-349800057344000000048947200020.250.25000.250.251. The fmancial results of the company have been prepared in accordance with Indian Accouting Standards (Ind AS) notified under the companies (Indian Accouting standards) Rules, 2015 as amended by the companies (Indian Accouting standards) (Amendment) rules,2016. <BR> <BR> 2. Since the principal customer of the company is an organisation that is controlled by the Government of India, the company has been assured of its Receivables and has not made any provision for loss allowance in the past and as on date. Hence the company has concluded that no provision for loss allowance needs to be made as on March 31, 2025. The company will reassess the model periodically and make the necessary adjustments for loss allowance if any, on case to case basis if required. <BR> <BR> 3. Imeds Global Private Limited is wholly owned subsidiary of Avantel Limited. <BR> <BR> 4. In the Consolidated Financial results, Employee benefit expenses include Rs. 365.24 Lakhs interms of Avantel <BR> Employee Stock Option Plan, 2023 for the quarter ending March 31, 2025 and Rs.1456.62 Lakhs for the year <BR> ending March 31, 2025. <BR> <BR> 5. During the year the company allotted 14,12,270 Equity Shares on December 26, 2024, 44,390 Equity Shares on January 27,2025 and 9,580 Equity Shares on February 26,2025, the options allotted to the employees in terms of Avantel Employee Stock Option Plan, 2023. <BR> <BR> 6. The Board of Directors has recommended a fmal dividend of Rs. 0.20 per equity share of Rs. 2/- each for the year ended 31 st March, 2025. <BR> <BR> 7. The aforementioned results are reviewed by the Audit Committee of the Board and susequently taken on record by the board of directors at its meeting held on April 26, 2025. <BR> <BR> 8. Figures for the previous year/period have been regrouped / reclassified where ever necessary to confirm to the current year's/ period's presentation <BR> <BR> 9. The results for the year ended March 31,2025 are also available on the BSE Limited and National Stock Exchange of India Limited websites and on the Company's website.2024-04-012025-03-31AuditedConsolidated24912620001788100025091430008373640000-1980620005395480003045800011803500038739900017147420007944010000794401000232161000-220600022995500005644460000000564446000-34980005609480000000489472000202.322.3002.322.3Other Expenses111451000Other Expenses38739900011036260004542900000000000029336000293360004511000431820001226084000604524000071239000019889000577750000708600079714000040000272678000167438200000290046600048947800018829830002372461000023724610001200000000005218700017218700098010000001819880009109300013890000276280004151800017542000030803100029412000085740000346017000005280050002900466000Communications and signal processing products496189000Health Care1246000Communications and signal processing products2502458000Health Care66850004974350002509143000004974350002509143000Communications and signal processing products95675000Health Care-10768000Communications and signal processing products827156000Health Care-3275500084907000794401000000084907000794401000Communications and signal processing products2677565000Health Care222901000290046600002900466000Communications and signal processing products497449000Health Care30556000528005000052800500030458000-144131000-706300000-508270000-108600000-1686600004900000118035000037120000904100000000000-448400013622100009933000804334000000305436000049889800000000000470900078385600000000000000000000095170000197091000-57253900000733120000000012000000023946000048654000234250000-148610008242600087850000878500011104000198890003498000349800000-3498000-3498000AuditedtrueGrandhy & cotrue2026-12-31